Verified Nov 2026
Batteries & E-Mobility
·

Newton, Massachusetts
·
Since 2008
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company headquartered in Newton, Massachusetts, founded in 2008. With 200–500 employees and estimated revenue of $100–250 million, the company develops oncology therapies targeting nuclear export dysregulation. Its lead product, XPOVIO® (selinexor), is an oral XPO1 inhibitor approved in the U.S. for blood cancers and solid tumors, with pipeline candidates including eltanexor and compounds for myelofibrosis.
Karyopharm Therapeutics Inc. at a glance
Revenue
$100-250M
Est. band
Employees
200-500
Founded
2008
Headquarters
Newton, Massachusetts
Industries
Automotive
Electric Vehicles
Medical
Overview
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company headquartered in Newton, Massachusetts, founded in 2008. With 200–500 employees and estimated revenue of $100–250 million, the company develops oncology therapies targeting nuclear export dysregulation. Its lead product, XPOVIO® (selinexor), is an oral XPO1 inhibitor approved in the U.S. for blood cancers and solid tumors, with pipeline candidates including eltanexor and compounds for myelofibrosis.
At a glance
Attribute | Detail |
|---|---|
Founded | 2008 |
Headquarters | Newton, Massachusetts |
Employees | 200-500 |
Revenue | $100-250M (estimated) |
Primary capability | Batteries & E-Mobility |
What Karyopharm Therapeutics Inc. makes
The company employs its proprietary SINE technology platform to develop small-molecule drugs that inhibit Exportin 1 (XPO1), a protein essential for cell transport, addressing high-unmet-need cancer indications.
Latest developments
2026-11-02 — Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future (karyopharm.com)
2026-08-13 — Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission - Aug 13, 2026 (karyopharm.com)
2026-02-12 — Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress - Feb 12, 2026 (karyopharm.com)
2025-10-08 — Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis - Oct 8, 2025 (karyopharm.com)
Company details
As a private, commercial-stage biotech firm, Karyopharm serves the oncology and medical sectors with clinical-stage advancement toward regulatory submissions, including a Phase 3 trial readout for myelofibrosis. Karyopharm Therapeutics Inc. was founded in 2008, has an estimated 200-500 employees, and is headquartered in Newton, Massachusetts.
Frequently asked questions
What does Karyopharm Therapeutics Inc. make?
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company headquartered in Newton, Massachusetts, founded in 2008. With 200–500 employees and estimated revenue of $100–250 million, the company develops oncology therapies targeting nuclear export dysregulation. Its lead product, XPOVIO® (selinexor), is an oral XPO1 inhibitor approved in the U.S. for blood cancers and solid tumors, with pipeline candidates including eltanexor and compounds for myelofibrosis.
Where is Karyopharm Therapeutics Inc. headquartered?
Karyopharm Therapeutics Inc. is headquartered in Newton, Massachusetts (85 Wells Avenue, Newton, Massachusetts, 02459).
When was Karyopharm Therapeutics Inc. founded?
Karyopharm Therapeutics Inc. was founded in 2008.
How big is Karyopharm Therapeutics Inc.?
Karyopharm Therapeutics Inc. has an estimated 200-500 employees, with revenue in the $100-250M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
